Avecho Biotechnology Beheer
Beheer criteriumcontroles 4/4
Avecho Biotechnology's CEO is Paul Gavin, appointed in May 2020, has a tenure of 4.5 years. total yearly compensation is A$291.80K, comprised of 77.8% salary and 22.2% bonuses, including company stock and options. directly owns 0.34% of the company’s shares, worth A$32.58K. The average tenure of the management team and the board of directors is 4.5 years and 7.2 years respectively.
Belangrijke informatie
Paul Gavin
Algemeen directeur
AU$291.8k
Totale compensatie
| Percentage CEO-salaris | 77.8% |
| Dienstverband CEO | 4.5yrs |
| Eigendom CEO | 0.3% |
| Management gemiddelde ambtstermijn | 4.5yrs |
| Gemiddelde ambtstermijn bestuur | 7.2yrs |
Recente managementupdates
Recent updates
Companies Like Avecho Biotechnology (ASX:AVE) Are In A Position To Invest In Growth
Jan 13
Here's Why We're Watching Avecho Biotechnology's (ASX:AVE) Cash Burn Situation
May 31Avecho Biotechnology (ASX:AVE) Is In A Good Position To Deliver On Growth Plans
Nov 04We're Hopeful That Avecho Biotechnology (ASX:AVE) Will Use Its Cash Wisely
Jul 14We Think Avecho Biotechnology (ASX:AVE) Can Afford To Drive Business Growth
Mar 23We're Not Very Worried About Avecho Biotechnology's (ASX:AVE) Cash Burn Rate
Dec 08
Analyse CEO-vergoeding
| Datum | Totale vergoeding | Salaris | Bedrijfswinsten |
|---|---|---|---|
| Jun 30 2024 | n/a | n/a | -AU$3m |
| Mar 31 2024 | n/a | n/a | -AU$3m |
| Dec 31 2023 | AU$292k | AU$227k | -AU$3m |
| Sep 30 2023 | n/a | n/a | -AU$4m |
| Jun 30 2023 | n/a | n/a | -AU$4m |
| Mar 31 2023 | n/a | n/a | -AU$3m |
| Dec 31 2022 | AU$355k | AU$227k | -AU$2m |
| Sep 30 2022 | n/a | n/a | -AU$2m |
| Jun 30 2022 | n/a | n/a | -AU$2m |
| Mar 31 2022 | n/a | n/a | -AU$3m |
| Dec 31 2021 | AU$477k | AU$227k | -AU$3m |
| Sep 30 2021 | n/a | n/a | -AU$3m |
| Jun 30 2021 | n/a | n/a | -AU$3m |
| Mar 31 2021 | n/a | n/a | -AU$3m |
| Dec 31 2020 | AU$497k | AU$231k | -AU$3m |
| Sep 30 2020 | n/a | n/a | -AU$2m |
| Jun 30 2020 | n/a | n/a | -AU$2m |
| Mar 31 2020 | n/a | n/a | -AU$739k |
| Dec 31 2019 | AU$235k | AU$200k | AU$850k |
| Sep 30 2019 | n/a | n/a | AU$504k |
| Jun 30 2019 | n/a | n/a | AU$158k |
| Mar 31 2019 | n/a | n/a | -AU$2m |
| Dec 31 2018 | AU$231k | AU$200k | -AU$4m |
| Jun 30 2018 | n/a | n/a | -AU$6m |
| Mar 31 2018 | n/a | n/a | -AU$7m |
| Dec 31 2017 | AU$238k | AU$200k | -AU$9m |
Compensatie versus markt: Paul's total compensation ($USD191.28K) is below average for companies of similar size in the Australian market ($USD299.27K).
Compensatie versus inkomsten: Paul's compensation has been consistent with company performance over the past year.
CEO
Paul Gavin
4.5yrs
Tenure
AU$291,796
Compensatie
Dr. Paul Gavin, BSc (Hons), PhD serves as Chief Executive Officer of Avecho Biotechnology Limited (formerly known as Phosphagenics Limited) since May 01, 2020 and served as its Chief Scientific Officer unt...
Leiderschapsteam
| Naam | Positie | Tenure | Compensatie | Eigendom |
|---|---|---|---|---|
| Chief Executive Officer | 4.5yrs | AU$291.80k | 0.34% A$ 32.6k | |
| Chief Operating Officer | 4.5yrs | AU$242.70k | 0.35% A$ 33.3k | |
| Company Secretary & CFO | 5.9yrs | geen gegevens | geen gegevens |
4.5yrs
Gemiddelde duur
Ervaren management: AVE's management team is considered experienced (4.5 years average tenure).
Bestuursleden
| Naam | Positie | Tenure | Compensatie | Eigendom |
|---|---|---|---|---|
| Independent Director | 9.6yrs | AU$65.32k | 0.11% A$ 10.0k | |
| Independent Non-Executive Chairman | 9.6yrs | AU$115.10k | 0.37% A$ 35.0k | |
| Chairman of Scientific Advisory Board | no data | geen gegevens | geen gegevens | |
| Independent Non-Executive Director | 4.8yrs | AU$65.32k | 0.053% A$ 5.0k | |
| Non-Executive Director | less than a year | geen gegevens | geen gegevens |
7.2yrs
Gemiddelde duur
62.5yo
Gemiddelde leeftijd
Ervaren bestuur: AVE's board of directors are considered experienced (7.2 years average tenure).